-- Announcement on Resolutions of the 9th Meeting of the 6th Board of Supervisors
Securities code: 603392 Securities abbreviation: Wantai Biotechnology Announcement number: 2025-041
Beijing Wantai Biopharmaceutical Co., Ltd.
Announcement of Resolutions of the Ninth Meeting of the Sixth Supervisory Board
The Company's Supervisory Committee and all supervisors guarantee that there are no false records, misleading statements or major omissions in this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
1. Convening of Supervisory Board Meetings
Beijing Wantai Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") sent the notice and meeting materials for the ninth meeting of the sixth session of the Supervisory Board to all supervisors via email on August 10, 2025. This meeting will be held by communication on August 20, 2025. This meeting was chaired by Mr. Xing Qingchao, Chairman of the Company's Board of Supervisors. 3 supervisors were supposed to be present, but 3 supervisors were actually present. The number of attendees, convening and voting methods of this meeting comply with the relevant provisions of the Company Law, other laws and regulations, and the Articles of Association, and are legal and valid.
2. Review status of the Supervisory Board meeting
- Reviewed and approved the "Full Text and Summary of the 2025 Semi-annual Report"
The Supervisory Board considers that:
(1) The preparation and review procedures for the company’s 2025 semi-annual report comply with the provisions of laws, regulations, the company’s articles of association and the company’s internal management system.
(2) The content and format of the company's 2025 semi-annual report comply with the regulations of the China Securities Regulatory Commission and the stock exchange, and the information contained can truly, accurately and completely reflect the company's operations, management and financial status in the 2025 semi-annual report from all aspects.
(3) Before putting forward this opinion, no personnel involved in the preparation and review of the 2025 semi-annual report were found to have violated confidentiality regulations.
For details, please refer to the full text and summary of the company's 2025 semi-annual report disclosed by the company in designated information disclosure media.
Voting results: 3 votes in favor, 0 votes against, and 0 abstentions.
- The "Proposal on the Special Report on the Deposit and Actual Use of Funds Raised by the Company in the Half-Year of 2025" was reviewed and approved.
For details, please refer to the "Special Report of Beijing Wantai Biopharmaceutical Co., Ltd. on the Storage and Actual Use of Funds Raised in the Half-Year of 2025" disclosed by the company in the designated information disclosure media (Announcement No.: 2025-042).
Voting results: 3 votes in favor, 0 votes against, and 0 abstentions.
Announcement is hereby made.
Board of Supervisors of Beijing Wantai Biopharmaceutical Co., Ltd.
August 21, 2025